Genetic testing of embryos, formally called preimplantation genetic testing (PGT), allows fertility clinics to screen IVF embryos for chromosomal abnormalities or inherited diseases before transferring them to the uterus. The technology has become routine in many IVF cycles, but its value depends heavily on who is using it and why. For some patients it substantially improves the chance of a healthy pregnancy; for others, the evidence suggests it adds cost and complexity without a clear benefit.
What the Biopsy Actually Involves
Genetic testing requires removing a few cells from the embryo for analysis, and the timing of that biopsy matters. The current standard is trophectoderm biopsy, performed around day five or six of development when the embryo has reached the blastocyst stage and contains roughly 100 to 200 cells. A handful of cells are taken from the outer layer, which will eventually form the placenta rather than the baby itself. This approach has largely replaced the older method of cleavage-stage biopsy, which removed one or two cells from a day-three embryo that had only about eight cells total.
The shift happened because cleavage-stage biopsy clearly damaged the embryo’s chances. A randomized trial found that removing a cell on day three cut sustained implantation from about 50% to 30%, a relative drop of 39%. Blastocyst-stage biopsy showed no such effect, with implantation rates essentially identical between biopsied and unbiopsied embryos.1PubMed. Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial From a practical standpoint, trophectoderm biopsy also yields more DNA to work with, which improves the accuracy of the genetic analysis.
Three Types of Testing and What Each Screens For
PGT is not one test. It comes in three main varieties, each designed to catch a different kind of genetic problem.
- PGT-A (aneuploidy): Screens for embryos with the wrong number of chromosomes, such as an extra copy of chromosome 21 (which causes Down syndrome) or a missing chromosome. Aneuploidy is the most common reason embryos fail to implant or miscarry, and it becomes far more frequent as a woman’s eggs age.
- PGT-M (monogenic): Tests for a specific inherited disease caused by a single gene, such as cystic fibrosis, sickle cell disease, or Huntington’s disease. It is available for any single-gene disorder where the disease-causing mutation has been identified.2PubMed Central. Preimplantation Genetic Testing for Monogenic Disorders Families typically pursue PGT-M because one or both partners are known carriers.
- PGT-SR (structural rearrangements): Identifies embryos affected by chromosomal rearrangements like translocations, where pieces of chromosomes have swapped places. People who carry balanced translocations are usually healthy themselves, but their embryos have a high risk of receiving unbalanced chromosomes, leading to repeated miscarriages or affected offspring.
PGT-M is the least controversial of the three. It targets a known mutation with high precision, and the clinical goal is straightforward: helping carrier couples have children free of a devastating inherited disease.3PubMed Central. OneGene PGT: comprehensive preimplantation genetic testing method utilizing next-generation sequencing PGT-SR, while more niche, also has clear evidence of benefit for translocation carriers. A study of reciprocal translocation carriers with histories of two or more pregnancy losses found that after PGT-SR treatment, about 86% of clinical pregnancies resulted in normal live births, with the miscarriage rate dropping to around 11%.4PubMed Central. Pregnancy outcomes of reciprocal translocation carriers with two or more unfavorable pregnancy histories: before and after preimplantation genetic testing
Who Benefits Most from PGT-A
PGT-A is where the real clinical debate lives. The technology was developed on the logic that selecting chromosomally normal embryos should improve success rates, but who exactly benefits has turned out to be complicated.
The case is strongest for women over 35. Aneuploidy rates climb steeply with maternal age, from roughly 30% of embryos in a woman’s early thirties to well over half by her late thirties and higher still after 40. A systematic review and meta-analysis found that PGT-A significantly improved clinical pregnancy rates per embryo transfer in women older than 35.5PubMed Central. Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis In one retrospective study, live birth rates for this group roughly doubled with PGT-A compared to conventional IVF.6PubMed. Performance of preimplantation genetic testing for aneuploidy in IVF cycles for patients with advanced maternal age, repeat implantation failure, and idiopathic recurrent miscarriage
Similarly, patients with repeated implantation failure or recurrent pregnancy loss appear to gain a clear advantage. A retrospective cohort study found that PGT-A roughly doubled the implantation rate and the ongoing pregnancy or live birth rate per transfer cycle for women with recurrent miscarriage and those with repeated implantation failure.7Clinical and Experimental Reproductive Medicine. Clinical outcomes of preimplantation genetic testing for aneuploidy in high-risk patients: A retrospective cohort study These are populations where a large share of embryos are aneuploid, so the screening catches a real problem with real frequency.
The Debate Over PGT-A in Good-Prognosis Patients
For younger women with plenty of good-quality embryos, the picture flips. A major randomized trial published in the New England Journal of Medicine compared PGT-A to conventional IVF in women under 36 who had at least three good-quality blastocysts. The cumulative live birth rate was actually higher in the conventional IVF group: about 82% compared to 77% with PGT-A. The PGT-A group did have fewer miscarriages, but they also ended up with fewer babies overall.8PubMed. Live Birth with or without Preimplantation Genetic Testing for Aneuploidy
This result does not mean PGT-A actively harmed those patients, but it does suggest that in young women who produce multiple good embryos, the testing primarily discards embryos that might have worked anyway, either because the test result was a false positive or because the embryo would have self-corrected its chromosomal issue. The trial’s conclusion was that conventional IVF was noninferior to PGT-A in this group.
Results from a single-center retrospective study told a different story, finding that the PGT-A subgroup had a higher per-transfer live birth rate than conventional IVF.9PubMed Central. Live birth rates with and without preimplantation genetic testing: a single-center retrospective study The discrepancy highlights a real tension in the field. Per-transfer success rates almost always look better with PGT-A because only screened embryos get transferred. But per-patient cumulative rates, meaning the total chance you take home a baby after using all your embryos, sometimes do not improve because some viable embryos get excluded by the screening process. This distinction matters when you are deciding whether testing is worth it for your situation.
Mosaicism and the Gray Zone
One of the biggest complications in embryo testing is mosaicism, where some cells in an embryo are chromosomally normal and others are not. When a biopsy grabs a few cells from the outer layer, those cells may not represent the whole embryo. The reported incidence of mosaicism in trophectoderm biopsies ranges widely, from about 4% to 32% depending on the lab and the detection technology used.10PubMed Central. The birth of a baby with mosaicism resulting from a known mosaic embryo transfer: a case report
Mosaic embryos create a clinical dilemma. The abnormal cells in the biopsy sample might be concentrated in the trophectoderm while the inner cell mass, which becomes the fetus, is normal. Research in both mouse models and human tissue has shown that developing embryos can actively eliminate aneuploid cells through programmed cell death, a process that appears to preferentially deplete abnormal cells from the embryonic lineage while tolerating them in what will become the placenta.11Nature Communications. Autophagy-mediated apoptosis eliminates aneuploid cells in a mouse model of chromosome mosaicism Work on human embryos has confirmed that aneuploidy declines starting around day three of development, with even a small percentage of normal cells apparently able to rescue the embryonic tissue in experimental models.12Nature Cell Biology. Depletion of aneuploid cells in human embryos and gastruloids
This self-correction ability means that some embryos labeled “abnormal” or “mosaic” by PGT-A could have become healthy babies if transferred. Many clinics now classify mosaic embryos on a spectrum, considering the percentage of abnormal cells and which chromosomes are involved, and some will transfer low-level mosaic embryos when no fully normal embryos are available. The decision is genuinely case-by-case, and it is one of the areas where genetic counseling before and after testing is most valuable.
How Accurate Is the Testing
No test is perfect, and PGT is no exception. A systematic review and meta-analysis covering 36 studies and over 4,200 embryos evaluated diagnostic accuracy across different sampling methods. Trophectoderm biopsy, the current standard, achieved a sensitivity of about 84% and specificity of about 79%, with an overall accuracy score of 0.878 out of 1. That means roughly one in six truly abnormal embryos may be missed, and roughly one in five normal embryos may be incorrectly flagged.13PubMed Central. The diagnostic accuracy of preimplantation genetic testing (PGT) in assessing the genetic status of embryos: a systematic review and meta-analysis
Accuracy varies by the type of testing. PGT-SR, which looks for structural rearrangements, performed considerably better, with an accuracy score of 0.957. This makes sense because structural rearrangements tend to create large, unambiguous chromosomal imbalances that are easier to detect than the subtler mosaicism patterns that complicate PGT-A results.
The same meta-analysis found that combining trophectoderm biopsy with analysis of spent culture medium, the fluid left behind after the embryo is removed, pushed the accuracy score to 0.927. Multiple biopsies from the same embryo achieved even higher accuracy at 0.966, though taking extra biopsies is not always practical. These findings reinforce that a single trophectoderm biopsy is good but not definitive, and patients should understand that a “normal” or “abnormal” result carries some uncertainty.
Safety for Babies Born After Testing
Parents considering PGT naturally worry about whether the biopsy itself could affect their child. The reassuring headline is that blastocyst biopsy does not appear to add measurable risk to newborn outcomes. A large follow-up study of over 1,700 children born after blastocyst biopsy found no significant differences in birth weight, gestational age, preterm birth rates, or rates of very low birth weight compared to IVF babies born without biopsy.14PubMed. Neonatal outcomes of live births after blastocyst biopsy in preimplantation genetic testing cycles: a follow-up of 1,721 children A separate study tracking children through age two confirmed that growth and developmental measures were comparable between biopsied and non-biopsied groups.15PubMed Central. Cleavage-stage or blastocyst-stage embryo biopsy has no impact on growth and health in children up to 2 years of age
There are some cautionary signals, though. A comprehensive review noted limited and sometimes conflicting data suggesting a possible association between embryo biopsy and an increased risk of hypertensive disorders during pregnancy for the mother. Some data also hinted at slightly higher rates of preterm delivery and birth defects following trophectoderm biopsy, though the review cautioned that these findings could be explained by other IVF-related procedures or by characteristics of the patient populations studied.16PubMed Central. Obstetric, neonatal, and child health outcomes following embryo biopsy for preimplantation genetic testing The honest assessment is that long-term data remain thin. Most studies follow children for only the first few years, and the technology has not been in widespread use long enough to have substantial data on teenagers or adults conceived after biopsy.
The Financial Equation
PGT-A typically adds several thousand dollars to an IVF cycle, and whether that investment pays off financially depends on the clinical scenario. One analysis found that for patients with more than one embryo available, PGT-A reduced overall treatment costs by $931 to $2,411 because it shortened the time in treatment by up to four months and reduced the number of failed transfers and miscarriages.17PubMed. Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage Fewer failed transfers mean fewer clinic visits, fewer frozen embryo transfer fees, and less time away from work.
But context matters enormously. A separate cost-effectiveness analysis looking at donor-egg cycles, where eggs come from young donors and aneuploidy rates are already low, found PGT-A was not cost-effective in nearly all modeled scenarios, adding over $6,000 per cycle with a cost per additional live birth exceeding $119,000.18PubMed Central. Cost-effectiveness of preimplantation genetic testing for aneuploidy for fresh donor oocyte cycles Insurance coverage for PGT varies widely. Some states mandate IVF coverage but may or may not include genetic testing; many patients pay entirely out of pocket. PGT-M and PGT-SR, because they address defined medical indications, are more commonly covered when insurance includes fertility benefits.
The Emotional Weight of Testing
Numbers and success rates only capture part of the experience. The decision to test, and then the wait for results, carries a psychological burden that often surprises people. Research has found that the process of deciding whether to pursue PGT is highly stressful and produces adverse emotional effects like distress and persistent uncertainty.19PubMed Central. Patients’ preimplantation genetic testing decision-making experience: an opinion on related psychological frameworks Studies have also found that people undergoing PGT report lower quality of life and positive emotions compared to those doing IVF without genetic testing, even at the very start of treatment.20Scientific Reports. The impact of preimplantation genetic testing on the quality of life of people undergoing assisted reproduction treatment
What happens after results arrive matters just as much. A study of decision regret following PGT-A found that while the overall level of regret was low, about 39% of respondents expressed some degree of it. The strongest predictor was the outcome: patients who ended up with few or no normal embryos felt significantly more regret than those who had euploid embryos to transfer. Similarly, anxiety spiked after a negative pregnancy test or miscarriage.21Human Reproduction. Beyond the biopsy: predictors of decision regret and anxiety following preimplantation genetic testing for aneuploidy Knowing that all your embryos are abnormal can feel devastating, even though the test is simply revealing information that was already there.
Polygenic Screening and the Expanding Frontier
A newer and far more controversial application is polygenic embryo screening, sometimes called PGT-P. Unlike PGT-M, which looks for a single gene with a known effect, polygenic scores attempt to estimate an embryo’s future risk for conditions shaped by hundreds or thousands of genetic variants, such as diabetes, heart disease, or even traits like height or educational attainment.
A small number of companies already sell this service, and it has drawn sharp criticism from geneticists. A detailed analysis in the New England Journal of Medicine outlined several problems. Polygenic scores developed from studies of adults lose much of their predictive power when applied to embryos, because they cannot account for environmental factors, gene-gene interactions, or the shared family environment that siblings will grow up in. The analysis also raised concerns about unintended consequences, including the possibility of inadvertently selecting against beneficial traits, widening social inequalities, and devaluing certain human characteristics.22PubMed Central. Problems with Using Polygenic Scores to Select Embryos Separate ethical analysis has noted that while polygenic screening is not yet widespread, it raises challenges around regulation and the boundaries of acceptable reproductive selection that many jurisdictions have barely begun to address.23PubMed Central. Polygenic risk scores and embryonic screening: considerations for regulation
How Regulation Varies Around the World
There is no global consensus on what kinds of embryo testing should be allowed. A comparative review of 19 countries found policy approaches ranging from highly restrictive to broadly permissive, with significant variation in how medical necessity is defined and whether nonmedical uses like sex selection are permitted.24PubMed Central. Regulating Preimplantation Genetic Testing across the World: A Comparison of International Policy and Ethical Perspectives Germany and Switzerland impose strict limits on embryo testing, while the United States has essentially no federal regulation, leaving decisions to clinics and patients. The United Kingdom takes a middle path through the Human Fertilisation and Embryology Authority, which licenses specific conditions for PGT on a case-by-case basis.
These differences drive cross-border reproductive travel. Patients routinely travel from countries with restrictive rules to more permissive ones to access testing they cannot get at home. Research has documented that legal barriers weigh more heavily than geographic distance in these decisions, with couples prepared to travel considerable distances for care unavailable in their home country.25Reproductive BioMedicine Online. Comparative preimplantation genetic diagnosis policy in Europe and the USA and its implications for reproductive tourism This creates a system where access to embryo testing correlates with wealth and mobility, raising equity concerns that sit alongside the technology’s medical promise.
Sex selection is one of the most contentious applications. PGT inherently reveals chromosomal sex, and in the United States it is legal to use this information for nonmedical “family balancing.” Most other countries ban sex selection for nonmedical reasons, viewing it as raising concerns about gender discrimination and social harm.26PubMed Central. Ethical considerations in sex selection The broader ethical discussion also touches on using PGT to screen for late-onset conditions like hereditary cancer syndromes, HLA matching so a child can serve as a tissue donor for a sick sibling, and conditions that some in the disability community do not consider diseases at all.27Human Reproduction. Extending preimplantation genetic diagnosis: the ethical debate
Non-Invasive Testing on the Horizon
The most promising technical advance may eventually sidestep the biopsy altogether. When embryos grow in culture, they shed small amounts of cell-free DNA into the surrounding fluid. Researchers have been developing non-invasive PGT (niPGT) that analyzes this spent culture medium instead of removing cells from the embryo.
Early results are encouraging. One study found that when stray cells from the mother were carefully removed, non-invasive testing had a zero false-negative rate and higher concordance with the embryo’s true chromosomal status than standard trophectoderm biopsy.28PubMed Central. Noninvasive preimplantation genetic testing for aneuploidy in spent medium may be more reliable than trophectoderm biopsy This advantage likely comes from the fact that the shed DNA reflects both the inner cell mass and the trophectoderm, giving a more complete picture than a biopsy of just the outer layer. Other groups have proposed using non-invasive testing as a backup when trophectoderm biopsy fails or gives inconclusive results.29PubMed Central. Noninvasive preimplantation genetic testing for aneuploidy using blastocyst spent culture medium may serve as a backup of trophectoderm biopsy in conventional preimplantation genetic testing
Non-invasive PGT is not yet ready to replace biopsy-based testing as a standalone method in clinical practice. The amount of cell-free DNA in culture medium is tiny, contamination risks are real, and large validation studies have not yet been completed. But if the technology matures, it could resolve the central tension of embryo testing: getting the genetic information you need without physically disturbing the embryo at all.